Medicamen Biotech Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has consistently been profitable over the last 5 years
- Company has a consistent dividend-paying track record
- Company maintains a comfortable, low leverage position
CONS
- Operating cash flow has been negative in recent years
- A large part of profit comes from other income (63.2% of PBT)
- Receivables are growing faster than sales - a possible quality concern
- Company has a low return on equity of 5.8% over last 3 years
- Company has a low return on capital employed of 8.4%
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.69x)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1864.00 | 36.98 | 447236.04 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9405.00 | 85.36 | 249673.20 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4928.40 | 85.95 | 187460.49 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1118.00 | 24.71 | 111520.93 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1380.00 | 33.08 | 111484.47 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1936.00 | 95.67 | 104604.45 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1669.00 | 25.87 | 96030.57 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| DRREDDY | 1140.80 | 29.55 | 95220.28 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| LUPIN | 2075.00 | 17.16 | 94882.67 | 0.87 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2246.00 | 45.42 | 92769.93 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2417.00 | 37.94 | 68213.70 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MEDICAMEQ | 307.00 | 38.45 | 416.38 | 0.33 | 1.85 | 15.30 | 47.90 | 11.26 | 5.77 | 9.03 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 | 44 | 46 | 47 | 43 | 45 | 45 | 30 | 43 | 47 | 47 | 61 | 48 | |
| 35 | 39 | 42 | 42 | 40 | 39 | 38 | 31 | 38 | 42 | 43 | 55 | 46 | |
| Operating Profit | 7 | 5 | 5 | 6 | 3 | 5 | 7 | -2 | 5 | 5 | 4 | 5 | 2 |
| OPM % | 16.57% | 10.66% | 10.52% | 12.15% | 8.01% | 11.87% | 14.84% | -5.44% | 10.73% | 10.94% | 9.34% | 8.97% | 3.57% |
| 0 | 1 | 1 | 1 | 1 | 0 | 0 | 5 | 0 | 0 | 1 | 2 | 1 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 0 | 2 | 2 | 2 | 2 | 2 |
| Profit before Tax | 5 | 2 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 3 | 2 | 5 | 3 |
| Tax % | 15.81% | 40.08% | 37.92% | 23.31% | 48.72% | 53.57% | 24.74% | 25.30% | 24.88% | 21.27% | 22.75% | 12.06% | 28.24% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 4 | 2 |
| 3.12 | 1.17 | 1.60 | 1.61 | 0.63 | 1.78 | 2.30 | 1.47 | 1.18 | 1.63 | 1.21 | 3.28 | 1.36 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 123 | 126 | 113 | 115 | 141 | 179 | 163 | 203 | |
| 105 | 106 | 93 | 91 | 117 | 156 | 148 | 186 | |
| Operating Profit | 17 | 19 | 20 | 24 | 24 | 24 | 14 | 17 |
| OPM % | 14.24% | 15.52% | 17.45% | 20.86% | 17.28% | 13.11% | 8.87% | 8.24% |
| 4 | 2 | 1 | 2 | 2 | 2 | 6 | 4 | |
| Interest | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 3 |
| Depreciation | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 |
| Profit before Tax | 18 | 18 | 16 | 18 | 17 | 13 | 10 | 12 |
| Tax % | 31.37% | 26.08% | 26.01% | 17.67% | 13.59% | 27.39% | 33.65% | 19.21% |
| Net Profit | 12 | 13 | 12 | 15 | 15 | 9 | 7 | 10 |
| EPS | 0.00 | 0.00 | 9.93 | 12.19 | 11.64 | 7.47 | 5.16 | — |
| Dividend Payout % | 9.73% | 4.60% | 10.07% | 8.20% | 8.59% | 13.39% | 19.39% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 5%
- 3 Years:
- 12%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -13%
- 3 Years:
- -24%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -22%
- 1 Year:
- -7%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 8%
- 3 Years:
- 6%
- Last Year:
- 3%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 13 | 13 | 13 |
| 75 | 109 | 121 | 134 | 178 | 194 | 200 | |
| 12 | 10 | 19 | 28 | 28 | 39 | 33 | |
| Trade Payables | 31 | 37 | 32 | 43 | 48 | 39 | 43 |
| 8 | 13 | 10 | 8 | 10 | 7 | 5 | |
| Total Liabilities | 137 | 181 | 194 | 225 | 277 | 292 | 294 |
| 24 | 34 | 90 | 92 | 93 | 92 | 87 | |
| Capital Work in Progress | 15 | 40 | 0 | 0 | 0 | 0 | 0 |
| 15 | 17 | 5 | 27 | 45 | 59 | 62 | |
| 0 | 0 | 0 | 0 | 0 | 55 | 69 | |
| Cash & Bank | 9 | 3 | 4 | 4 | 21 | 15 | 4 |
| 74 | 87 | 95 | 102 | 118 | 71 | 72 | |
| Total Assets | 137 | 181 | 194 | 225 | 277 | 292 | 294 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 8 | 17 | 17 | 7 | -3 | -7 | -8 | |
| Cash from Investing | -15 | -37 | -18 | -8 | -6 | -6 | -1 |
| Cash from Financing | -4 | 19 | 6 | 4 | 29 | 6 | -1 |
| -14 | -5 | 1 | -0 | 17 | -6 | -11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-05 - Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-03 - Medicamen Biotech Limited has informed the Exchange regarding 'Submission of Integrated Annual Report for FY 2025-26 and Notice of the 33rd Annual General Meeting ( AGM ) of Medicamen Biotech Limited ( the Company ) to be held through Video Conferencing/Other Audio-Visual Means ( VC/OAVM ) on September 26, 2026 '.
2026-09-03 - Medicamen Biotech Limited has informed the Exchange regarding 'Submission of Business Responsibility and Sustainability Report for the financial year 2025-26'.
2026-08-18 - Medicamen Biotech Limited has informed the Exchange regarding 'Intimation of Book Closure and Record Date in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) '.
2026-08-17 - Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Medicamen Biotech Limited has informed the Exchange regarding 'Closure of Register of Members and Share Transfer Books'.
2026-08-14 - Medicamen Biotech Limited has informed the Exchange that Record date for the purpose of Dividend is 19-Sep-2026.
2026-08-14 - Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-28 - Medicamen Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
News
Recent coverage and analyst commentary for MEDICAMEQ
Loading news…
AI Stock Analyst
Medicamen Biotech Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account